Disease · MONDO_0002146

hypogonadism

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. hypogonadism. Diseases, record MONDO_0002146. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002146

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: hypogonadism; Open Targets
Open Targets ID: MONDO_0002146; Open Targets
Other names: gonadotropin deficiency, hypogonadotropism; Open Targets
Disease Ontology: DOID:1924; Disease Ontology
MeSH: D007006; MeSH
NCI Thesaurus: C9227; NCI Thesaurus
Highest stage of its drugs: Approval, for 17 of its 39 drugs, from DailyMed, EMA Human Drugs, FDA and TTD; Open Targets

Drugs39

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TESTOSTERONE	CHEMBL386630	Small molecule	Approval	DailyMed	99	69	69	Drugs and targets
TESTOSTERONE UNDECANOATE	CHEMBL2107067	Small molecule	Approval	DailyMed and TTD	29	26	26	Drugs and targets
TESTOSTERONE ENANTHATE	CHEMBL1200335	Small molecule	Approval	DailyMed	10	8	8	Drugs and targets
ESTRADIOL	CHEMBL135	Small molecule	Approval	DailyMed	46	5	5	Drugs and targets
TESTOSTERONE CYPIONATE	CHEMBL1201101	Small molecule	Approval	DailyMed	22	4	4	Drugs and targets
CHORIOGONADOTROPIN ALFA	CHEMBL1201464	Protein	Approval	DailyMed	2	1	0	Drugs and targets
ESTROGENS, CONJUGATED	CHEMBL1201649		Approval	DailyMed	2	1	1	Drugs and targets
BROMOCRIPTINE MESYLATE	CHEMBL1200503	Small molecule	Approval	DailyMed and FDA	4	0	0	Drugs and targets
ESTRADIOL VALERATE	CHEMBL1511	Small molecule	Approval	DailyMed	3	0	0	Drugs and targets
ESTROPIPATE	CHEMBL1200980	Small molecule	Approval	DailyMed and TTD	2	0	0	Drugs and targets

1 to 10 of 39

See all 39 drugs

Targets15

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ESR1	Estrogen receptor	9	Estrogen receptor agonist; Estrogen receptor alpha agonist; Estrogen receptor alpha modulator; Estrogen receptor modulator	Approval	https://conductscience.org/library/genes/2099	Drugs and targets
AR	Androgen receptor	6	Androgen Receptor agonist	Approval	https://conductscience.org/library/genes/367	Drugs and targets
GNRHR	Gonadotropin-releasing hormone receptor	6	Gonadotropin-releasing hormone receptor agonist; Gonadotropin-releasing hormone receptor antagonist	Phase 1/2	https://conductscience.org/library/genes/2798	Drugs and targets
ESR2	Estrogen receptor	3	Estrogen receptor agonist; Estrogen receptor modulator	Approval	https://conductscience.org/library/genes/2100	Drugs and targets
FSHR	Follicle-stimulating hormone receptor	3	Follicle stimulating hormone receptor agonist	Approval	https://conductscience.org/library/genes/2492	Drugs and targets
CYP19A1	Aromatase	2	Cytochrome P450 19A1 inhibitor	Phase 3	https://conductscience.org/library/genes/1588	Drugs and targets
DRD2	D2-like dopamine receptor	2	D2-like dopamine receptor agonist	Approval	https://conductscience.org/library/genes/1813	Drugs and targets
DRD3	D2-like dopamine receptor	2	D2-like dopamine receptor agonist	Approval	https://conductscience.org/library/genes/1814	Drugs and targets
DRD4	D2-like dopamine receptor	2	D2-like dopamine receptor agonist	Approval	https://conductscience.org/library/genes/1815	Drugs and targets
LHCGR	Lutropin-choriogonadotropic hormone receptor	2	Luteinizing hormone/Choriogonadotropin receptor agonist	Approval	https://conductscience.org/library/genes/3973	Drugs and targets

1 to 10 of 15

See all 15 targets

Trials118

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03518034	A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men	Phase 4	5,246	2024-03-13	Hypogonadism, Cardiovascular Diseases	TESTOSTERONE	Its record names the disease	ClinicalTrials.gov
NCT01143818	ESPRIT Study in Hypogonadal Men		1,053	2011-09-26	Hypogonadism	TESTOSTERONE	Its record names the disease	ClinicalTrials.gov
NCT01816295	A Study in Men With Low Testosterone to Measure the Effects of Testosterone Solution on Testosterone Levels, Sex Drive and Energy	Phase 3	715	2015-10-02	Hypogonadism	TESTOSTERONE	Its record names the disease	ClinicalTrials.gov
NCT04456296	A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism	Phase 4	673	2025-03-14	Hypogonadism, Hypogonadism, Male, Hypogonadotropic Hypogonadism	TESTOSTERONE	Its record names the disease	ClinicalTrials.gov
NCT00467870	Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men	Phase 3	531	2017-03-07	Hypogonadism, Primary Hypogonadism, Secondary Hypogonadism	TESTOSTERONE UNDECANOATE	Its record names the disease	ClinicalTrials.gov
NCT01403116	Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men	Phase 3	325	2018-08-14	Male Hypogonadism	TESTOSTERONE, TESTOSTERONE UNDECANOATE	Its record names the disease	ClinicalTrials.gov
NCT03198728	Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men	Phase 3	314	2023-06-28	Hypogonadism, Male	TESTOSTERONE, TESTOSTERONE UNDECANOATE	Its record names the disease	ClinicalTrials.gov
NCT01446042	Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism	Phase 3	306	2018-06-13	Male Hypogonadism	TESTOSTERONE	Its record names the disease	ClinicalTrials.gov
NCT00433199	Testosterone Treatment for Hypogonadal Men	Phase 3	274	2011-12-08	Hypogonadism	TESTOSTERONE	Its record names the disease	ClinicalTrials.gov
NCT04274894	A Study of the Effect of Topical Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism	Phase 4	246	2022-12-15	Hypogonadism	TESTOSTERONE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 118

See all 118 trials

Comparisons in its trials42

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
AndroGel 1.62% vs Placebo: Time From Randomization to First Clinical Fracture: Number and Percentage of Participants With an Event	91 of 2,601	64 of 2,603	5,204	NCT03518034	Trial comparisons
AndroGel 1.62% vs Placebo: Tertiary Endpoint: Incidence Rate of Heart Failure	55 of 2,596	50 of 2,602	5,198	NCT03518034	Trial comparisons
AndroGel 1.62% vs Placebo: Tertiary Endpoint: Incidence Rate of All Cause Mortality	144 of 2,596	148 of 2,602	5,198	NCT03518034	Trial comparisons
AndroGel 1.62% vs Placebo: Tertiary Endpoint: Incidence Rate of Prostate Cancer	12 of 2,596	11 of 2,602	5,198	NCT03518034	Trial comparisons
AndroGel 1.62% vs Placebo: Time From Randomization to the First Component Event of Major Adverse Cardiac Event (MACE): Number and Percentage of Participants With an Event	182 of 2,596	190 of 2,602	5,198	NCT03518034	Trial comparisons
AndroGel 1.62% vs Placebo: Tertiary Endpoint: Incidence Rate of Acute Urinary Retention	20 of 2,596	16 of 2,602	5,198	NCT03518034	Trial comparisons
AndroGel 1.62% vs Placebo: Tertiary Endpoint: Incidence Rate of Pharmacologic Treatment for Lower Urinary Tract Symptoms	101 of 2,596	87 of 2,602	5,198	NCT03518034	Trial comparisons
AndroGel 1.62% vs Placebo: Tertiary Endpoint: Incidence Rate of Peripheral Arterial Revascularization	30 of 2,596	33 of 2,602	5,198	NCT03518034	Trial comparisons
AndroGel 1.62% vs Placebo: Tertiary Endpoint: Incidence Rate of Invasive Prostate Surgical Procedures for Benign Prostatic Hyperplasia	23 of 2,596	12 of 2,602	5,198	NCT03518034	Trial comparisons
AndroGel 1.62% vs Placebo: Incidence of High-Grade Prostate Cancer	5 of 2,596	3 of 2,602	5,198	NCT03518034	Trial comparisons

1 to 10 of 42

See all 42 comparisons in its trials

Papers from its trials48

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
32250330	RESULT	1	PubMed
23343764	RESULT	1	PubMed
21717386	RESULT	1	PubMed
21689131	RESULT	1	PubMed
21252493	RESULT	1	PubMed
20378927	RESULT	1	PubMed
18046048	RESULT	1	PubMed
16260965	RESULT	1	PubMed
40246046	DERIVED	1	PubMed
40090688	DERIVED	1	PubMed

1 to 10 of 48

See all 48 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0002146

GET https://conductscience.org/api/diseases/v1/MONDO_0002146/drugs?page=2

API reference For AI assistants